PureTech Health (LON:PRTC) Shares Down 15.2% – Here’s What Happened

Shares of PureTech Health plc (LON:PRTCGet Free Report) dropped 15.2% during trading on Tuesday . The stock traded as low as GBX 117.20 ($1.50) and last traded at GBX 117.20 ($1.50). Approximately 42,764,352 shares traded hands during mid-day trading, an increase of 2,645% from the average daily volume of 1,557,904 shares. The stock had previously closed at GBX 138.20 ($1.77).

Wall Street Analysts Forecast Growth

Separately, Jefferies Financial Group reiterated a “buy” rating and set a GBX 455 ($5.81) price target on shares of PureTech Health in a research note on Monday, December 16th.

Check Out Our Latest Research Report on PRTC

PureTech Health Stock Performance

The stock has a market cap of £352.05 million, a PE ratio of -4.81 and a beta of 1.02. The stock has a fifty day moving average of GBX 138.62 and a 200-day moving average of GBX 149.16. The company has a quick ratio of 2.51, a current ratio of 3.68 and a debt-to-equity ratio of 45.82.

About PureTech Health

(Get Free Report)

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule.

Read More

Receive News & Ratings for PureTech Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PureTech Health and related companies with MarketBeat.com's FREE daily email newsletter.